DE60305026T2 - 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten - Google Patents

3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten Download PDF

Info

Publication number
DE60305026T2
DE60305026T2 DE60305026T DE60305026T DE60305026T2 DE 60305026 T2 DE60305026 T2 DE 60305026T2 DE 60305026 T DE60305026 T DE 60305026T DE 60305026 T DE60305026 T DE 60305026T DE 60305026 T2 DE60305026 T2 DE 60305026T2
Authority
DE
Germany
Prior art keywords
pain
pharmaceutically acceptable
disease
compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60305026T
Other languages
German (de)
English (en)
Other versions
DE60305026D1 (de
Inventor
M. Pfizer Global Research a KAWAMURA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of DE60305026D1 publication Critical patent/DE60305026D1/de
Application granted granted Critical
Publication of DE60305026T2 publication Critical patent/DE60305026T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60305026T 2002-04-26 2003-04-15 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten Expired - Fee Related DE60305026T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37593902P 2002-04-26 2002-04-26
US375939P 2002-04-26
PCT/IB2003/001556 WO2003091241A1 (en) 2002-04-26 2003-04-15 3, 4-dihydroquinolin-2(1h)-one compounds as nr2b receptor antagonists

Publications (2)

Publication Number Publication Date
DE60305026D1 DE60305026D1 (de) 2006-06-08
DE60305026T2 true DE60305026T2 (de) 2006-10-12

Family

ID=29270728

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60305026T Expired - Fee Related DE60305026T2 (de) 2002-04-26 2003-04-15 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten

Country Status (15)

Country Link
US (1) US6713490B2 (https=)
EP (1) EP1499606B8 (https=)
JP (1) JP2005524696A (https=)
AR (1) AR039663A1 (https=)
AT (1) ATE325117T1 (https=)
AU (1) AU2003219398A1 (https=)
BR (1) BR0309778A (https=)
CA (1) CA2483636A1 (https=)
DE (1) DE60305026T2 (https=)
ES (1) ES2258716T3 (https=)
MX (1) MXPA04010549A (https=)
PA (1) PA8572601A1 (https=)
TW (1) TW200406402A (https=)
UY (1) UY27776A1 (https=)
WO (1) WO2003091241A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
MXPA06003748A (es) * 2003-10-08 2006-06-14 Pfizer Compuestos de lactama condensada.
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
JPWO2005097782A1 (ja) * 2004-04-07 2007-08-16 協和醗酵工業株式会社 ピペリジン誘導体
HU226977B1 (en) * 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
EP2334176A4 (en) 2008-09-27 2012-05-02 Taraxos Inc TOPICAL FORMULATIONS FOR THE TREATMENT OF NERVE DISEASES
US20120077883A1 (en) * 2009-03-31 2012-03-29 De Barros Coelho Claudia Couto Treatment of tinnitus and associated auditory dysfunctions
WO2011145062A1 (en) 2010-05-21 2011-11-24 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
WO2012042314A1 (en) 2010-10-02 2012-04-05 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
AU2013251079B2 (en) 2012-04-20 2017-03-23 Ucb Pharma S.A. Methods for treating Parkinson's disease
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902695A (en) 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
KR0163355B1 (ko) 1990-05-10 1998-12-01 알렌 제이. 스피겔 신경보호성 인돌론 및 관련 유도체
US5852040A (en) 1992-10-30 1998-12-22 Pfizer Inc. Neuroprotective 3,4-dihydro-2(1H)-quinolone compounds
PE20020291A1 (es) 2000-08-21 2002-04-17 Hoffmann La Roche Profarmacos para ligandos del receptor nmda

Also Published As

Publication number Publication date
EP1499606B8 (en) 2006-08-30
PA8572601A1 (es) 2004-12-16
AU2003219398A1 (en) 2003-11-10
MXPA04010549A (es) 2005-02-17
US6713490B2 (en) 2004-03-30
JP2005524696A (ja) 2005-08-18
DE60305026D1 (de) 2006-06-08
BR0309778A (pt) 2005-03-08
ES2258716T3 (es) 2006-09-01
TW200406402A (en) 2004-05-01
CA2483636A1 (en) 2003-11-06
WO2003091241A1 (en) 2003-11-06
EP1499606B1 (en) 2006-05-03
US20030216430A1 (en) 2003-11-20
UY27776A1 (es) 2003-11-28
ATE325117T1 (de) 2006-06-15
AR039663A1 (es) 2005-03-02
EP1499606A1 (en) 2005-01-26

Similar Documents

Publication Publication Date Title
DE69627852T2 (de) Verbindungen, die an einer neuen stelle auf rezeptor-stimulierten kalziumkanälen wirksam sind, verwendbar zur behandlung von neurologischen krankheiten
DE60305026T2 (de) 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten
DE69631390T2 (de) Substituierte Benzylaminpiperidin-Verbindungen
DE60303381T2 (de) Neue indolylpiperidin-derivate als potente antihistaminische und antiallergische mittel
DE60318583T2 (de) N-äphenyl(piperidin-2-yl)methylübenzamid-derivate, verfahren zu deren herstellung und ihre therapeutische verwendung
DE60012031T2 (de) Piperazin verbindungen als tachykinin-antagonisten
TW202045477A (zh) 用於治療腦機能障礙的氮呯-吲哚及其他雜環
DE60114227T2 (de) 2,4-substituierte pyridinderivate
DE60111621T2 (de) Decahydro-isochinolinderivate
DE60316672T2 (de) Polycyclische verbindungen als potente alpha2-adrenoceptor antagonisten
DE69016530T2 (de) 1,3-Dihydro-1-(pyridinylamino)-2H-indol-2-one, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel.
JP3831255B2 (ja) ４−ベンジル−１−〔２−（４−ヒドロキシフェノキシ）エチル〕ピペリジン−３，４−ジオール
DE602005005064T2 (de) Neue 4-benzylidenpiperidinderivate
DE60213629T2 (de) Piperidinverbindungen als muscarinantagonisten
DD216716A5 (de) Verfahren zur herstellung von octahydrobenzo (f)chinolinen
DE102004054634A1 (de) Azaindolcarboxamide
DE69410509T2 (de) Benzoxazinderivate, deren Herstellung und deren Verwendung in Therapie
WO2023028091A1 (en) Deuterated empathogens
DE69612753T2 (de) (r)-5-bromo-n-(1-ethyl-4-methylhexahydro-1h-1,4-diazepin-6-yl)-2-methoxy-6-methylamino-3-pyridincarboxamid, verfahren zu seinerherstellung und dieses enthaltende medizinische zubereitung
DE60034577T2 (de) In 4-stellung substituierte piperidinderivate
DE69002338T2 (de) Pyrrolidin-Derivate und ihre pharmazeutische Verwendung.
JP2007508289A (ja) Ｎｍｄａ受容体拮抗薬としての１−［２−（４−ヒドロキシフェニル）−２−ヒドロキシエチル］−ピペリジン−４−オール化合物
DE60130691T2 (de) Indolderivate zur Behandlung von Erkrankungen des Zentralnervensystems
DE60013418T2 (de) Morpholinderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
DE602005006018T2 (de) Arylpiperazinderivate und deren verwendung als für den dopamin-d3-rezeptor selektive liganden

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: PFIZER INC., NEW YORK, N.Y., US

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee